Search - tctmd.com

Displaying 21 - 40 of 147

Sort: Relevancy | Date

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

Intravascular Ultrasound Supported Endovascular Therapy in SFA Disease: 12-Month Results From the IVORY Study

Presenter: Osamu Iida

September 26, 2019

Presentation TCT 2019

Emerging Drug-Free Platforms for the SFA: Can We Do Better Off Drugs?

Presenter: William Gray

September 26, 2019

Presentation TCT 2019

Deciphering the FDA Guidance

Presenter: Mehdi Shishehbor

September 26, 2019

Presentation TCT 2019

State of the Art Lecture: Novel Drug Delivery Technologies for the SFA

Presenter: Juan Granada

September 26, 2019

Presentation TCT 2019

Introduction and Session Objectives

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

My Toughest SFA Case of the Year

Presenter: Subhash Banerjee

September 25, 2019

News Daily News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

Caitlin E. Cox

August 15, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

Presentation ISET 2019

5-Year Results from the IN.PACT SFA Randomized Trial

Presenter: Gary Ansel

January 30, 2019

Presentation ISET 2019

Drug-Coated Therapy for ISR: Review of Options and Data

Presenter: Brian DeRubertis

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Caitlin E. Cox

October 05, 2018

Advertisement

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Intravascular Ultrasound Supported Endovascular Therapy in SFA Disease: 12-Month Results From the IVORY Study

Emerging Drug-Free Platforms for the SFA: Can We Do Better Off Drugs?

Deciphering the FDA Guidance

State of the Art Lecture: Novel Drug Delivery Technologies for the SFA

Introduction and Session Objectives

My Toughest SFA Case of the Year

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

5-Year Results from the IN.PACT SFA Randomized Trial

Drug-Coated Therapy for ISR: Review of Options and Data

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content